Ying He

US Patent:

20110213765, Sep 1, 2011

Filed:

May 20, 2010

Appl. No.:

12/783621

Inventors:

Liang CUI - Beijing, CN
Hailing XU - Peking, CN
Ying HE - Palo Alto CA, US

Assignee:

VMware, Inc. - Palo Alto CA

International Classification:

G06F 17/30
G06F 9/455
G06F 21/00

US Classification:

707711, 718 1, 707741, 726 1, 707E17002, 707E17108, 707E17032, 707769

Abstract:

A method includes indexing data and/or metadata in online virtual machines (VMs), offline VMs, virtual applications, and/or snapshots thereof on one or more host server(s) in a virtualization environment through a search architecture in the virtualization environment. The online VMs are VMs that are powered on, and the offline VMs are VMs that are powered off. The method also includes maintaining a database of the indexed data and/or metadata in the online VMs, the offline VMs, the virtual applications, and/or the snapshots thereof to enable a comprehensive search result to a search query through the search architecture. The database is associated with the search architecture.

US Patent:

20120041844, Feb 16, 2012

Filed:

Aug 3, 2011

Appl. No.:

13/197577

Inventors:

Jianjun SHEN - Beijing, CN
Ying HE - Palo Alto CA, US

Assignee:

VMWARE, INC. - Palo Alto CA

International Classification:

G06Q 30/00

US Classification:

705 2661

Abstract:

In one aspect, a method includes publishing an object of a user such that another user can search for the object by means of a user interface. The object may be an application, an application group, an application component, and/or a service. The object runs on a platform. The platform may be a hypervisor, an application container, a mobile platform, and/or a computer. The method includes permitting another user to access the object based on a transacting for the object between the users. The transaction may involve a clone transaction, a grant transaction, an application component transaction or a service transaction. A tax may be levied based on the transaction. A scope of the access of the object to another user is based on a transaction protocol, which is based on the transacting between the users. The transaction protocol may include a payment scheme, a term, or a set of object rights.

US Patent:

20130198319, Aug 1, 2013

Filed:

Jan 31, 2012

Appl. No.:

13/362341

Inventors:

Jianjun SHEN - Beijing, CN
Ying HE - Palo Alto CA, US
Hailing XU - Peking, CN
Howie XU - Sunnyvale CA, US
Juntao LIU - Beijing, CN
Shudong ZHOU - Fremont CA, US

Assignee:

VMWARE, INC. - Palo Alto CA

International Classification:

G06F 15/16
G06F 9/455

US Classification:

709217, 718 1

Abstract:

Embodiments monitor application performance metrics representing the performance of a software application executed by one or more host computing devices. Based on the application of rules to the application performance metrics, an elasticity action, such as a power-on action, a power-off action, a deploy action, and/or a destroy action, is determined. The elasticity action is transmitted to one or more target hosts, which perform the elasticity action. The target host may be selected based on host performance metrics. Further, a load balancing service may accommodate the addition of a new software application instance to a cluster and/or the removal of an existing software application instance from the cluster.

US Patent:

20140059310, Feb 27, 2014

Filed:

May 31, 2013

Appl. No.:

13/907393

Inventors:

Ying HE - Palo Alto CA, US
Yunshan LU - San Jose CA, US

International Classification:

G06F 3/06

US Classification:

711162

Abstract:

A virtualized computing system for executing a distributed computing application, such as Hadoop, is discussed. The virtualized computing system stores data in a distributed filesystem, such as Hadoop Distributed File System, and processes data using a topology awareness that takes into account the virtualization layer of the virtualized computing system. The virtualized computing system employs locality-related policies, including replica placement policies, replica choosing policies, balancer policies, and task scheduling policies that take advantage of the awareness of the virtualization topology.

US Patent:

20190374533, Dec 12, 2019

Filed:

Jan 9, 2018

Appl. No.:

16/476838

Inventors:

- Fremont CA, US
Marc NAVRE - Fremont CA, US
Christopher CARRERAS - Fremont CA, US
Noah BELL - Fremont CA, US
Michael R. LEADBETTER - Fremont CA, US
Jeffrey W. JACOBS - Fremont CA, US
Irina DOTSENKO - Fremont CA, US
Dean DRAGOLI - Fremont CA, US
Ying HE - Fremont CA, US
Andrew KING - Fremont CA, US
Jason LEWIS - Fremont CA, US
Matthew SIEGEL - Fremont CA, US

Assignee:

Ardelyx, Inc. - Fremont CA

International Classification:

A61K 31/4725
A61K 9/00
A61K 45/06

Abstract:

The present disclosure is directed to compounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome proliferator-activated receptor (PPAR) gamma agonist-induced fluid retention. The present disclosure is also directed to compounds and methods for the treatment of hypertension. The present disclosure is also directed to compounds and methods for the treatment of gastrointestinal tract disorders, including the treatment or reduction of pain associated with gastrointestinal tract disorders. The methods generally comprise administering to a mammal in need thereof a pharmaceutically effective amount of a compound, or a pharmaceutical composition comprising such a compound, that is designed to be substantially active in the gastrointestinal (GI) tract to inhibit NHE-mediated antiport of sodium ions and hydrogen ions therein. More particularly, the method comprises administering to a mammal in need thereof a pharmaceutically effective amount of a compound, or a pharmaceutical composition comprising such a compound, that inhibits NHE-3, -2 and/or -8 mediated antiport of sodium and/or hydrogen ions in the GI tract and is designed to be substantially impermeable to the layer of epithelial cells, or more specifically the epithelium of the GI tract. As a result of the compound being substantially impermeable, it is not absorbed and is thus essentially systemically non-bioavailable, so as to limit the exposure of other internal organs (e.g., liver, heart, brain, etc.) thereto. The present disclosure is still further directed to a method wherein a mammal is administered such a compound with a fluid-absorbing polymer, such that the combination acts as described above and further provides the ability to sequester fluid and/or salt present in the GI tract.

US Patent:

20170368004, Dec 28, 2017

Filed:

Jan 9, 2017

Appl. No.:

15/402213

Inventors:

- Fremont CA, US
Christopher CARRERAS - Belmont CA, US
Michael Robert LEADBETTER - San Leandro CA, US
Jason Gustaf LEWIS - Castro Valley CA, US
Jeffrey W. JACOBS - San Mateo CA, US
Irina DOTSENKO - San Jose CA, US
Dean DRAGOLI - Los Altos CA, US
Ying HE - Pleasanton CA, US
Andrew KING - Dublin CA, US
Matthew SIEGEL - Menlo Park CA, US

International Classification:

A61K 31/17
A61K 31/25
A61K 31/167
A61K 31/03
A61K 31/4545
A61K 31/18
A61K 31/015
A61K 31/10

Abstract:

The present disclosure is directed to compounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome proliferator-activated receptor (PPAR) gamma agonist-induced fluid retention. The present disclosure is also directed to compounds and methods for the treatment of hypertension. The present disclosure is also directed to compounds and methods for the treatment of gastrointestinal tract disorders, including the treatment or reduction of pain associated with gastrointestinal tract disorders.

US Patent:

20170340623, Nov 30, 2017

Filed:

Jan 9, 2017

Appl. No.:

15/402211

Inventors:

- Fremont CA, US
Marc NAVRE - Belmont CA, US
Christopher CARRERAS - Belmont CA, US
Noah BELL - Berkeley CA, US
Michael Robert LEADBETTER - San Leandro CA, US
Jeffrey W. JACOBS - San Mateo CA, US
Irina DOTSENKO - San Jose CA, US
Dean DRAGOLI - Los Altos CA, US
Ying HE - Pleasanton CA, US
Andrew KING - Dublin CA, US
Jason LEWIS - Castro Valley CA, US
Matthew SIEGEL - Menlo Park CA, US

International Classification:

A61K 31/4725
A61K 45/06
A61K 9/00

Abstract:

The present disclosure is directed to compounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome proliferator-activated receptor (PPAR) gamma agonist-induced fluid retention. The present disclosure is also directed to compounds and methods for the treatment of hypertension. The present disclosure is also directed to compounds and methods for the treatment of gastrointestinal tract disorders, including the treatment or reduction of pain associated with gastrointestinal tract disorders. The methods generally comprise administering to a mammal in need thereof a pharmaceutically effective amount of a compound, or a pharmaceutical composition comprising such a compound, that is designed to be substantially active in the gastrointestinal (GI) tract to inhibit NHE-mediated antiport of sodium ions and hydrogen ions therein. More particularly, the method comprises administering to a mammal in need thereof a pharmaceutically effective amount of a compound, or a pharmaceutical composition comprising such a compound, that inhibits NHE-3, -2 and/or -8 mediated antiport of sodium and/or hydrogen ions in the GI tract and is designed to be substantially impermeable to the layer of epithelial cells, or more specifically the epithelium of the GI tract. As a result of the compound being substantially impermeable, it is not absorbed and is thus essentially systemically non-bioavailable, so as to limit the exposure of other internal organs (e.g., liver, heart, brain, etc.) thereto. The present disclosure is still further directed to a method wherein a mammal is administered such a compound with a fluid-absorbing polymer, such that the combination acts as described above and further provides the ability to sequester fluid and/or salt present in the GI tract.

US Patent:

20160127206, May 5, 2016

Filed:

Jan 14, 2016

Appl. No.:

14/996081

Inventors:

- Palo Alto CA, US
Ying He - Palo Alto CA, US
Da Wan - Beijing, CN
Jun Xiao - Beijing, CN

International Classification:

H04L 12/26
H04L 29/08

Abstract:

A method receives physical location information for racks in which application running environments are located. Each rack includes multiple host computing devices in a cluster of host computing devices. Application running environment-rack associations are generated using the physical location information for the cluster where an application running environment-rack association maps an application running environment to a rack. The application running environment-rack associations are provided to the cluster. Then, the method provides a data set for storing in the cluster of hosts where the data set is associated with a placement strategy. The cluster uses the placement strategy to store a data block in the data set for a first application running environment and store a replica data block for a second application running environment at a location in the cluster based on the first application running environment being associated with a first rack from the application running environment-rack associations.